Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities

. The ground‐breaking discovery of genotype–phenotype relationships in hereditary medullary thyroid cancer has greatly facilitated early prophylactic thyroidectomy. Its timing depends not solely on a positive gene test but, more importantly, on the type of the REarranged during Transfection (RET) mutation and its underlying mode of RET receptor tyrosine kinase activation. In the past decade, the therapeutic corridor opened by molecular information has been defined down to a remarkable level of detail. Based on mutational risk profiles, preemptive thyroidectomy is recommended at 6 months of age for carriers of highest‐risk mutations, before the age of 5 years for carriers of high‐risk mutations, and before the age of 5 or 10 years for carriers of least‐high‐risk mutations. Additional lymph node dissection may not be needed in the absence of increased preoperative basal calcitonin levels. Better comprehension of RET function should enable the design of targeted therapies for RET carriers beyond surgical cure in whom the DNA‐based ‘window of opportunity’ has been missed.